NCT00388154View on ClinicalTrials.gov

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Endometrial Cancer
Interventions
DRUG

Gemcitabine

900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.

DRUG

Cisplatin

30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.

Trial Locations (3)

77030

St. Lukes Episcopal Hospital, Houston

UT MD Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00388154 - Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter